Nevertheless, if the proportion of GnRH agonist users without a SEER registry diagnosis is extrapolated to national figures (with 40% of the over 200,000 new prostate cancer cases in the United States receiving GnRH agonists), it could translate to several thousand men a year [1,4]. The gene discussed is GNRH1; the disease is prostate cancer.